Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CD4+ T Cells from Peripheral Blood of a Melanoma Patient Recognize Peptides Derived from Nonmutated Tyrosinase

CD4+ T Cells from Peripheral Blood of a Melanoma Patient Recognize Peptides Derived from... Tyrosinase is an antigen that is expressed by normal melanocytes as well as melanoma cells, against which responses by autologous T cells have been detected. Although CD4 + T cells play an important role in tumor immunity in animal tumor models, little information about CD4 + T-cell immunity against human tumors exists. Here, we report that CD4 + T cells from the peripheral blood of a patient with melanoma respond to synthetic peptides derived from nonmutated tyrosinase. T-cell clones were generated that recognized the tyrosinase p386–406 peptide when it was presented by the HLA-DR15 ( DRB1*1501 ) molecule. The CD4 + T-cell clone also recognized autologous EBV-transformed B-lymphoblastoid cell lines that had been pulsed with the lysate of melanoma cells. The synthetic tyrosinase p386–406 peptide was capable of binding to HLA-DR15 ( DRB1*1501 ) molecules on cell surface of DR15 homozygous cells. Thus, the finding that nonmutated tyrosinase peptides are immunogenic in a melanoma patient may provide the basis for the development of cancer immunotherapy, based on knowledge of synthetic tumor-associated peptide antigens. 1 To whom requests for reprints should be addressed, at Department of Pathology, Asahikawa Medical College, Nishikagura 4-5-3-11, Asahikawa, 078, Japan. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

CD4+ T Cells from Peripheral Blood of a Melanoma Patient Recognize Peptides Derived from Nonmutated Tyrosinase

CD4+ T Cells from Peripheral Blood of a Melanoma Patient Recognize Peptides Derived from Nonmutated Tyrosinase

Cancer Research , Volume 58 (2): 296 – Jan 15, 1998

Abstract

Tyrosinase is an antigen that is expressed by normal melanocytes as well as melanoma cells, against which responses by autologous T cells have been detected. Although CD4 + T cells play an important role in tumor immunity in animal tumor models, little information about CD4 + T-cell immunity against human tumors exists. Here, we report that CD4 + T cells from the peripheral blood of a patient with melanoma respond to synthetic peptides derived from nonmutated tyrosinase. T-cell clones were generated that recognized the tyrosinase p386–406 peptide when it was presented by the HLA-DR15 ( DRB1*1501 ) molecule. The CD4 + T-cell clone also recognized autologous EBV-transformed B-lymphoblastoid cell lines that had been pulsed with the lysate of melanoma cells. The synthetic tyrosinase p386–406 peptide was capable of binding to HLA-DR15 ( DRB1*1501 ) molecules on cell surface of DR15 homozygous cells. Thus, the finding that nonmutated tyrosinase peptides are immunogenic in a melanoma patient may provide the basis for the development of cancer immunotherapy, based on knowledge of synthetic tumor-associated peptide antigens. 1 To whom requests for reprints should be addressed, at Department of Pathology, Asahikawa Medical College, Nishikagura 4-5-3-11, Asahikawa, 078, Japan.

Loading next page...
 
/lp/american-association-of-cancer-research/cd4-t-cells-from-peripheral-blood-of-a-melanoma-patient-recognize-0dq15PymQg

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 1998 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

Tyrosinase is an antigen that is expressed by normal melanocytes as well as melanoma cells, against which responses by autologous T cells have been detected. Although CD4 + T cells play an important role in tumor immunity in animal tumor models, little information about CD4 + T-cell immunity against human tumors exists. Here, we report that CD4 + T cells from the peripheral blood of a patient with melanoma respond to synthetic peptides derived from nonmutated tyrosinase. T-cell clones were generated that recognized the tyrosinase p386–406 peptide when it was presented by the HLA-DR15 ( DRB1*1501 ) molecule. The CD4 + T-cell clone also recognized autologous EBV-transformed B-lymphoblastoid cell lines that had been pulsed with the lysate of melanoma cells. The synthetic tyrosinase p386–406 peptide was capable of binding to HLA-DR15 ( DRB1*1501 ) molecules on cell surface of DR15 homozygous cells. Thus, the finding that nonmutated tyrosinase peptides are immunogenic in a melanoma patient may provide the basis for the development of cancer immunotherapy, based on knowledge of synthetic tumor-associated peptide antigens. 1 To whom requests for reprints should be addressed, at Department of Pathology, Asahikawa Medical College, Nishikagura 4-5-3-11, Asahikawa, 078, Japan.

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Jan 15, 1998

There are no references for this article.